UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Shobie Ramakrishnan |
| b) | Position/status | Chief Digital and Technology Officer |
| c) | Initial notification/amendment | Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GSK plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
| b) | Nature of the transaction | Following the vesting on 19 August 2024 of 25% of an award made on 19 August 2019 under the GlaxoSmithKline Deferred Investment Award Programme, Ms Ramakrishnan will receive a cash payment of $99,026.66 less applicable tax withholding in respect of 2,385.035 notional ADSs. |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $41.5200 | 2,385.035 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2024-08-19 |
| f) | Place of the transaction | N/A |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| | GSK plc |
| | (Registrant) |
| | |
| Date: August 21, 2024 | |
| | |
| | By:/s/ VICTORIA WHYTE -------------------------- |
| | |
| | Victoria Whyte |
| | Authorised Signatory for and on |
| | behalf of GSK plc |
